UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 120

Sortiert nach

Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison

European urology, 2014-04, Vol.65 (4), p.755-765

2014

Volltextzugriff (PDF)

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Neurourology and urodynamics, 2014-01, Vol.33 (1), p.17-30

2014

Volltextzugriff (PDF)

Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause

Health and quality of life outcomes, 2023-11, Vol.21 (1), p.1-126, Article 126

2023

Volltextzugriff (PDF)

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep

Journal of patient-reported outcomes, 2021-04, Vol.5 (1), p.37-37, Article 37

2021

Volltextzugriff (PDF)

Use of Steroids in COVID-19 Patients: What is known?

Journal of the College of Physicians and Surgeons--Pakistan, 2022-03, Vol.32 (3), p.407-408

2022

Volltextzugriff (PDF)

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

Therapeutic advances in urology, 2015-08, Vol.7 (4), p.167-179

2015

Volltextzugriff (PDF)

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Therapeutic advances in urology, 2017-06, Vol.9 (6), p.137-154

2017

Volltextzugriff (PDF)

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

International journal of urology, 2014-10, Vol.21 (10), p.960-967

2014

Volltextzugriff (PDF)

Clinical outcome of paediatric patients with traumatic brain injury (TBI) receiving 3% hypertonic saline (HTS) in the emergency room of a tertiary care hospital

Journal of the Pakistan Medical Association, 2019-11, Vol.69 (11), p.1741

2019

Volltextzugriff (PDF)

A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?

European urology, 2016-11, Vol.70 (5), p.799-805

2016

Volltextzugriff (PDF)

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep

Journal of patient-reported outcomes, 2021-06, Vol.5 (1), p.42-42, Article 42

2021

Volltextzugriff (PDF)

The Role of Serotonin (5-Hydroxytryptamine 1A and 1B) Receptors in Prostate Cancer Cell Proliferation

The Journal of urology, 2006-10, Vol.176 (4), p.1648-1653

2006

Volltextzugriff (PDF)

The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy

Therapeutic Advances in Urology, 2018-08, Vol.10 (8), p.243-256

2018

Volltextzugriff (PDF)

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

BJU international, 2012-12, Vol.110 (11), p.1767-1774

2012

Volltextzugriff (PDF)

Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501–9

European urology, 2019-03, Vol.75 (3), p.e59-e60

2019

Volltextzugriff (PDF)

The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation

BJU international, 2006-03, Vol.97 (3), p.634-639

2006

Volltextzugriff (PDF)

Unintentional, paediatric domestic injury in a semi rural area of Karachi

Journal of the Pakistan Medical Association, 2012-07, Vol.62 (7), p.638-643

2012

Volltextzugriff (PDF)

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis

European urology, 2018-09, Vol.74 (3), p.324-333

2018

Volltextzugriff (PDF)

The role of serotonin in tumour growth (review)

Oncology reports, 2005-12, Vol.14 (6), p.1593

2005

Volltextzugriff (PDF)

Inaccuracies in the recently published review on mirabegron

International Urogynecology Journal, 2014-02, Vol.25 (2), p.295-295

Siddiqui, Emad

2014

Volltextzugriff (PDF)

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Expert opinion on investigational drugs, 2021-07, Vol.30 (7), p.681-694

2021

Volltextzugriff (PDF)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review

BMJ open, 2018-11, Vol.8 (11), p.e021889-e021889

2018

Volltextzugriff (PDF)

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

European urology, 2017-09, Vol.72 (3), p.389-399

2017

Volltextzugriff (PDF)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

Contemporary clinical trials communications, 2016-12, Vol.4 (C), p.199-207

2016

Volltextzugriff (PDF)

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden

Menopause (New York, N.Y.), 2021-05, Vol.28 (8), p.875

2021

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(120)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(78)
Humans
(51)
Male
(32)
Urology & Nephrology
(30)
Female
(28)
Urology
(22)
Overactive Bladder
(21)
Urinary Bladder, Overactive - Drug Therapy
(20)
Mirabegron
(19)
Aged
(18)
General & Internal Medicine
(16)
Medicine, General & Internal
(16)
Medicine, Research & Experimental
(16)
Middle Aged
(16)
Research & Experimental Medicine
(16)
Treatment Outcome
(16)
Adult
(11)
Biological And Medical Sciences
(11)
Medical Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause

Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep

Use of Steroids in COVID-19 Patients: What is known?

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

Clinical outcome of paediatric patients with traumatic brain injury (TBI) receiving 3% hypertonic saline (HTS) in the emergency room of a tertiary care hospital

A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?

Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep

The Role of Serotonin (5-Hydroxytryptamine 1A and 1B) Receptors in Prostate Cancer Cell Proliferation

The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation

Unintentional, paediatric domestic injury in a semi rural area of Karachi

Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis

The role of serotonin in tumour growth (review)

Inaccuracies in the recently published review on mirabegron

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden

Suchergebnisse filtern